PomegraHealthcare
MAJOR
1d ago5 min read
Humana (HUM) Jumps 15% on 2027 Medicare Star Ratings
Humana shares surged about 15% after its largest Medicare Advantage contract rose to 4 stars, while Alignment Healthcare fell more than 20% on a downgrade.
Pomegra Newswire
Healthcare News
Healthcare, pharma, and biotech market news: drug approvals, trial results, and the deals reshaping the sector.
AllMarketsEconomyBusiness & EarningsTechnologyHealthcarePolicy & RegulationGeopoliticsCommunity & Media
Healthcare
NOTABLE
2d ago4 min read
Haemonetics (HAE) Jumps 17% as CSL Plans Full U.S. Rollout
Haemonetics shares rose as much as 17% premarket Thursday after CSL said it will deploy NexSys PCS plasma devices at all U.S. centers by the end of 2027.
Healthcare
NOTABLE
3d ago5 min read
Option Care Health (OPCH) $5.8B Take-Private Explained
McKesson (MCK) and CD&R will buy Option Care Health for $32.05 a share in a $5.8 billion take-private, lifting OPCH stock about 33% on Tuesday, Oct. 6.
Healthcare
NOTABLE
3d ago4 min read
Moderna Stock Falls 6% After Nasdaq-100 Rally
Moderna (MRNA) shares fell about 6% on profit-taking after a 52-week high, days before the biotech replaces Warner Bros. Discovery in the Nasdaq-100 on Oct. 9.
Healthcare
MAJOR
4d ago5 min read
Option Care (OPCH) Agrees $5.8B McKesson, CD&R Buyout
McKesson and CD&R will take Option Care Health private at $32.05 a share, a $5.8 billion deal, after the stock jumped 21% on reports of advanced talks.
Healthcare
NOTABLE
4d ago5 min read
AstraZeneca Closes $2B Summit Therapeutics Stake
AstraZeneca completed its $2 billion equity investment in Summit Therapeutics, lifting SMMT about 17% premarket as the cancer-drug tie-up moves to trials.
Healthcare
MAJOR
5d ago5 min read
Vaxcyte Surges 50% as VAX-31 Wins Phase 3 Trial
Vaxcyte (PCVX) shares jumped about 50% after VAX-31 met every primary endpoint in a pivotal Phase 3 trial against Pfizer's Prevnar 20 and Merck's Capvaxive.
Healthcare
MAJOR
Sep 304 min read
Liquidia (LQDA) Plunges After Patent Loss to UTHR
Liquidia shares fell more than 50% after a Delaware court found Yutrepia infringed a United Therapeutics patent, while UTHR stock rose 12% on the ruling.
Healthcare
NOTABLE
Sep 304 min read
Moderna (MRNA) Drops 6% as Citi Downgrades to Sell
Moderna shares fell about 6% to near $190 after Citi cut the stock to Sell with an $80 target, saying a 223% rally overshot what cancer vaccine sales can justify.
Healthcare
MAJOR
Sep 295 min read
Iovance (IOVA) Soars 30% After 2026 Guidance Raise
Iovance Biotherapeutics (IOVA) raised its 2026 revenue guidance to $410–420 million on Amtagvi demand, and its shares jumped more than 30% on September 29, 2026.
Healthcare
MAJOR
Sep 295 min read
SMMT Surges 17% on AstraZeneca's $2B Equity Stake
AstraZeneca pays $2 billion for a 12% stake in Summit Therapeutics (SMMT), validating its ivonescimab pipeline and launching a joint gastrointestinal cancer combination program.
Healthcare
SEISMIC
Sep 284 min read
KOD Soars 150% as DAYBREAK Trial Hits Every Mark
Kodiak Sciences' DAYBREAK Phase 3 trial for Zenkuda hit every primary endpoint in wet AMD, sending KOD surging ~150% and triggering a massive short squeeze.
Healthcare
MAJOR
Sep 255 min read
CRL Surges to 52-Week High on 2030 Strategy Unveil
Charles River Laboratories (CRL) jumped 5.7% at its September 24 Investor Day after lifting 2026 earnings guidance and projecting 5-7% annual organic revenue growth through 2030 alongside a ~24%…
Healthcare
MAJOR
Sep 245 min read
Langone Eyes $2,000 for Eli Lilly in 3-4 Years
Ken Langone told CNBC that Eli Lilly (LLY) could reach $2,000 in three to four years, citing a $17-18B annual R&D budget and pipeline depth well beyond GLP-1s.
Healthcare
MAJOR
Sep 235 min read
TLX Drops 10% as $1.65B ITM Deal Triggers Dilution Selloff
Telix Pharmaceuticals (TLX) fell nearly 10% after its $1.65B acquisition of ITM Isotope Technologies Munich created a radiopharmaceutical powerhouse with $1.3B in pro forma revenue across 65+…
Healthcare
MAJOR
Sep 215 min read
Novo Nordisk Plunges 7% as 2030 Targets Disappoint
NVO shares slid as much as 9% after its Capital Markets Day in London, as a $23B pipeline target and patent-cliff questions hammered investor confidence in the Wegovy maker's growth story.
Healthcare
MAJOR
Sep 186 min read
XENE Plunges ~29% as Psychiatry Trial Halted, Epilepsy NDA Filed
Xenon Pharmaceuticals shares collapsed nearly 29% after the company voluntarily paused new enrollment in its Phase 3 depression trials citing neuropsychiatric adverse events, even as it filed a…
Healthcare
MAJOR
Sep 174 min read
LGVN Crashes 57% as ELPIS II Stem Cell Trial Fails
Longeveron's laromestrocel missed its primary endpoint in 40 HLHS infants, triggering a 57% stock crash and a full strategic review as the company's cash runway narrows into year-end.
Healthcare
MAJOR
Sep 166 min read
Biotech VC Hits $500M as Capital Rotates From AI
Biotech venture funding surpassed $500 million in a single week, with Solstice Oncology and Encoded Therapeutics anchoring a $75 million gene-therapy raise as institutional capital shifts away…
Healthcare
NOTABLE
Sep 116 min read
Elevance Health ELV Reaffirms 2026 Guidance, Stock Gains 4.1%
Elevance Health shares climbed 4.1% after the managed-care insurer proactively reaffirmed full-year 2026 EPS and benefit expense guidance, standing out as one of the session's rare defensive…
Healthcare
MAJOR
Sep 106 min read
Novartis NVS Under Fire After Triple Drug Disaster
Artisan Partners is demanding a Novartis board overhaul and M&A strategy reset after three consecutive clinical failures erased roughly $30 billion in market value, with NVS stock staging a…
Healthcare
MAJOR
Sep 95 min read
Roivant Sciences Surges 24% on PH-ILD Trial Win
Pulmovant's mosliciguat becomes the first drug to meet a Phase 2 primary endpoint in pulmonary hypertension with interstitial lung disease, a disease with zero approved treatments, vaulting ROIV…
Healthcare
MAJOR
Sep 85 min read
BSX Drops as Cyberattack Erases 2026 Earnings Guidance
Boston Scientific (BSX) warns it will miss 2026 EPS guidance after an August 25 cyberattack halted manufacturing and global order fulfillment, the first major med-tech guidance withdrawal tied to…
Healthcare
SEISMIC
Sep 76 min read
Lp(a) Drug Class Shaken as Pelacarsen Trial Fails
Novartis's pelacarsen missed the primary endpoint in the 8,323-patient Lp(a)HORIZON trial Sept. 7, raising the unsettling question of whether lowering lipoprotein(a) prevents cardiovascular events…
Healthcare
SEISMIC
Sep 55 min read
Ultragenyx (RARE) Crashes 47% on GTX-102 Failure
Ultragenyx RARE fell 47% after GTX-102 missed every primary and secondary endpoint in the ASPIRE Phase 3 Angelman syndrome study, triggering mass downgrades.
Healthcare
SEISMIC
Sep 45 min read
Ultragenyx RARE Crashes 47% on Angelman Trial Wipeout
Ultragenyx Pharmaceutical shares collapsed nearly 47% after apazunersen failed every endpoint in the Phase 3 Aspire Angelman study, erasing $1.14 billion in market value and forcing a strategic…
Healthcare
MAJOR
Sep 35 min read
NVS Surges 4% on Remibrutinib Phase 3 MS Win
Novartis's remibrutinib cleared every Phase 3 hurdle in relapsing MS, sending NVS up 4% and intensifying the battle for a $40 billion disease market.
Healthcare
MAJOR
Sep 37 min read
JNJ Prints $276.50 Record as Stagflation Fortress Trade Peaks
Johnson & Johnson shares hit an all-time high of $276.50 as the most aggressive institutional defensive rotation of 2026 floods capital into J&J's diversified pharma-medtech franchise and 54-year…
Healthcare
NOTABLE
Sep 28 min read
PFE Reaches Post-2024 High as Healthcare ETF Draws Bids
Pfizer (PFE) climbs to its highest close since October 2024 while Solventum posts a 52-week record as capital rotates into defensive dividend-paying healthcare.
Healthcare
MAJOR
Sep 17 min read
VEEV Holds 15% Surge as Vault CRM Displaces Salesforce
Veeva Systems sustains a post-earnings rally exceeding 15% into September after a beat-and-raise quarter confirms Vault CRM's structural displacement of Salesforce Health Cloud in life sciences.
Why is healthcare news different?
Healthcare investing runs on binary events. A drug trial readout or an FDA approval decision can double a biotech or cut it in half overnight, because a small company's whole valuation may rest on one molecule. The desk covers those catalysts - trial results, approvals, and the label details that decide a drug's market - alongside the steadier earnings of large pharma, insurers, and device makers.
The sector is also the classic defensive play: people need medicine in every economy, so healthcare earnings hold up when cyclical sectors roll over. Coverage links each story to the wiki entries on the science terms and the sector mechanics, so a headline about a Phase 3 miss explains itself.
Frequently Asked
Why are biotech stocks so volatile?
Small biotech valuations often rest on one or two drug candidates, so trial results and FDA decisions can reprice the whole company overnight.